Drug Profile
Research programme: proline dehydrogenase inhibitors - Calithera Biosciences
Alternative Names: Proline oxidase inhibitors - CalitheraLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Calithera Biosciences
- Class Small molecules
- Mechanism of Action Oxidoreductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Breast-cancer in USA
- 22 Apr 2015 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 106th Annual Meeting of the American Association for Cancer Research (AACR-2015)
- 22 Apr 2015 Early research in Breast cancer in USA (unspecified route)